ReviewFrontiers in pharmacology2026
The immunothrombosis pathway linking pulmonary disease to stroke and neurodegeneration: mechanisms and therapeutic implications.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary diseases increasingly reshape vascular biology and coagulation beyond the lung. Across acute infections and acute respiratory distress syndrome (ARDS), chronic airway inflammation (e.g., COPD), sleep-disordered breathing, fibrotic interstitial lung disease, and particulate air pollution, convergent immune programs couple inflammation to coagulation through immunothrombosis. Physiologic immunothrombosis can confine pathogens within the microvasculature, but dysregulated thromboinflammation drives endotheliopathy, platelet-leukocyte cooperation, neutrophil extracellular trap (NET) formation, complement activation, tissue factor-thrombin signaling, and fibrinolytic shutdown, culminating in microvascular thrombosis and organ injury. Emerging clinical and translational data suggest that these same modules may reshape stroke biology: NET-rich thrombi are linked to recanalization failure and thrombolysis resistance; systemic endotheliopathy can destabilize the blood-brain barrier and promote no-reflow; and complement-coagulation crosstalk amplifies neurovascular injury. Beyond acute events, chronic microvascular thrombosis and blood-brain barrier leakage allow fibrin(ogen) and coagulation proteases to signal through microglia and protease-activated receptors, potentially coupling vascular dysfunction to cognitive decline and neurodegenerative trajectories. Here we integrate convergent but independently derived evidence from pulmonary medicine, coagulation biology, stroke pathology, and neurodegeneration research into a lung-to-brain immunothrombosis framework. Because these evidence streams have developed largely in parallel, this synthesis represents a mechanistic integration hypothesis-intended to identify shared therapeutic nodes and guide cross-disciplinary validation-rather than a demonstrated biological sequence. We outline biomarker-guided strategies that pair conventional antithrombotics with targeted anti-thromboinflammatory approaches (NET-, complement-, and endothelial/adhesion-directed) while managing bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.